Disclosures: Tarik Asselah: Nothing to Disclose, Anca Streinu-Cercel: Nothing to Disclose, Alina Jucov: Nothing to Disclose, Edward Gane: Nothing to Disclose, Heiner Wedemeyer: Nothing to Disclose, Pietro Lampertico: ROCHE PHARMA/DIAGNOSTICS, GILEAD SCIENCES, GSK, ABBVIE, JANS: Advisor, Michael Chattergoon: Nothing to Disclose, Sophia Chow: Nothing to Disclose, Pan Wu: Nothing to Disclose, Cara Pilowa: Nothing to Disclose, Todd Correll: Nothing to Disclose, Carey Hwang: Vir Biotechnology, Inc: Employee and stock holder, Kosh Agarwal: Nothing to Disclose 2626 CANCER-INDUCED REPROGRAMMING OF MACROPHAGE NUCLEOTIDE METABOLISM DISMANTLES ANTI-TUMOR IMMUNITY Shuang Liang 1 Chuanli Zhou 2 Zhenyu Zhong 1 , 1 University of Texas Southwestern Medical Center, 2 UT Southwestern Medical Center Background: By establishing a pro-inflammatory and pro-tumorigenic environment within the liver, tumor-associated macrophages (TAMs) play a crucial role in propelling the progression of hepatocellular carcinoma (HCC) the dominant form of primary liver cancer
This surge is driven by increasing consumer health consciousness, the rising prevalence of lactose intolerance, and a growing demand for functional foods as healthier alternatives to conventional dairy products
The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma
121 Garca-BermdezM.FreudeK.MouhammadZ.van WijngaardenP.MartinK.KolkoM
